Table 2. The distribution of clinical and epidemiological characteristics according to the CKD stages of the 142 patients with predialysis CKD.
| Characteristic | Stages of CKD | p-value | ||
|---|---|---|---|---|
| Stages 2 & 3 | Stage 4 | Stage 5 | ||
| N | 57 | 70 | 15 | |
| Age* | 65.3±12.9 | 63.2±17.4 | 60.2±22.1 | 0.506 |
| BMI* | 27.6±4.4 | 25.7±4.8 | 23.6±2.4 | 0.007a |
| Diabetic | ||||
| Yes (%) | 27 (47.3) | 24 (34.2) | 7 (46.7) | 0.400 |
| No (%) | 30 (52.7) | 46 (65.8) | 8 (53.3) | |
| Use of statin | ||||
| Yes (%) | 37 (64.9) | 38 (54.2) | 8 (53.3) | 0.601 |
| No (%) | 20 (35.1) | 32 (45.8) | 7 (46.7) | |
| No of medications | 4.4±2.1 | 4.4±2.2 | 4.6±2.2 | 0.926 |
*ANOVA, post hoc Bonferroni test
**Pearson’s chi-squared test
a Difference between the patients with Stage 2 and 3 versus those with Stage 4